Leflunomid Egis (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, preventing the synthesis of pyrimidines needed for DNA replication. This limits the proliferation of activated T‑lymphocytes and reduces the release of inflammatory cytokines, thereby moderating the autoimmune response that drives arthritis.

The specific dose of Leflunomid Egis is determined by the prescribing physician based on the individual’s clinical condition, disease severity, and response to therapy. Patients should follow the dosing regimen provided by their healthcare professional.

Leflunomid Egis is classified as pregnancy category X because it is teratogenic and can cause fetal harm. It should not be used by pregnant women or women planning pregnancy, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Leflunomide differs from traditional DMARDs such as methotrexate by targeting pyrimidine synthesis rather than folate metabolism. It offers an oral alternative with a distinct safety profile, but clinicians often consider drug‑specific factors like liver function, blood pressure, and potential teratogenicity when selecting therapy.

Leflunomid Egis should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain its stability and potency.

Leflunomid Egis is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water and follow any specific instructions regarding timing or concomitant medications.

The most serious risks include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and bone‑marrow suppression leading to anemia, leukopenia, or thrombocytopenia. Patients should be monitored regularly for liver enzymes, blood counts, and any signs of severe skin or systemic reactions.

Leflunomid Egis is contraindicated in pregnant women, women planning pregnancy, and individuals with severe liver disease. Patients with uncontrolled hypertension, active infections, or known hypersensitivity to leflunomide should also avoid using this medication.